GW PHARMACEUTICALS, A DRUG COMPANY THAT SPECIALIZES IN CANNABIS-BASED PHARMACEUTICALS, HAS RECEIVED EARLY APPROVAL ON A PATENT COVERING THE USE OF MARIJUANA CHEMICALS FOR TREATING BRAIN CANCER.
GW Pharmaceuticals announced Wednesday that it has been issued a Notice of Allowance from the U.S. Patent Office for a patent application involving the use of THCand CBD, the two main chemicals in marijuana, for treating gliomas.
Once a patent application is deemed a genuine invention, the Patent Office sends a Notice of Allowance that outlines the fees involved with final approval.
Specifically, the company provides this description of the patent:
“The subject patent specifically covers a method for treating glioma in a human using a combination of cannabidiol (CBD) and tetrahydrocannabinol (THC) wherein the cannabinoids are in a ratio of from 1:1 to 1:20 (THC:CBD) with the intent to reduce cell viability, inhibit cell growth or reduce tumor volume.”
Filed in 2009, GW’s patent application lists Otsuka Pharmaceutical as a collaborator and initially claimed the invention of the “use of a combination of cannabinoids in the manufacture of a medicament for use in the treatment of cancer.”